Life and health industry financing report in the first half of 2017

Source: shihuochuang 2017-07-31 life and health industry mainly refers to the industries related to human physical and mental health, including life and health manufacturing industry and life and health service industry Among them, the life and health manufacturing industry mainly includes biotechnology products, biomedicine, medical devices, nutrition and health care products, fitness devices and rehabilitation equipment, etc.; the life and health service industry mainly includes medical services, health management, rehabilitation care, health care, fitness, etc Population aging, policy driven, industry technology accumulation and people's demand for health promote the development of China's big health industry According to the report data of Huoshi creation, the scale of China's life and health industry in 2012 was 1.8 trillion yuan, and by 2016 it had reached 3.2 trillion yuan According to the publicly disclosed investment and financing data, in the first half of 2017, 179 domestic life and health industries disclosed financing, 104 of which explicitly disclosed financing amount, involving an amount of 19.362 billion yuan, with an average financing amount of about 186 million yuan for a single transaction Among them, there are 35 single financing of more than RMB 100 million and 4 financing of more than RMB 100 million Artificial intelligence, precision medicine (molecular diagnosis, targeted treatment), POCT, non-public medical and other key words for industrial financing in the first half of 2017 The comparison of financing situation in the same period of three years compared with 275 financing in 2016 H1, totaling 20.612 billion yuan and 324 and 33.624 billion yuan in 2015 H1 The number of financing and disclosure amount of life health industry H1 in 2017 were significantly lower than those in the past two years Compared with the financing stage of H1 life and health industry in the past three years, the most obvious feature is that in 2017, the financing frequency of H1 seed / Angel round decreased significantly, and the proportion of round B and round C increased greatly It can be seen that a large number of projects have entered a stable growth period in 2017 From the perspective of life and health industry segmentation, the financing volume of medical service industry has been more than 50% In 2017, H1 medical service industry disclosed 105 times of financing, accounting for about 58.66% of the total number of financing In addition, in the first half of this year, the number of financing disclosed by the pharmaceutical and medical device industries increased compared with the previous two years Details of H1 financing in 2017 from the perspective of industry financing stage, the financing stage of life health industry in the first half of 2017 is mainly focused on round C and before Among them, 66 cases of financing occurred in round a, with a clear disclosure of financing amount of about 2.38 billion yuan; 35 cases were disclosed in round angel and round B, with a clear disclosure amount of about 167 million yuan and 5.299 billion yuan respectively Among them, 13 enterprises were merged and acquired, involving 9.912 billion yuan of people According to the regional distribution of industrial financing, Beijing, Guangdong, Shanghai, Zhejiang and Jiangsu are the most active areas of life health industrial capital in the first half of 2017 Among them, Beijing, the capital city, is the place where the most financing takes place, with 57 times of public disclosure of financing, involving financing enterprises such as noconda, tianguangshi, aijitaikang, etc.; 44 times of financing for enterprises located in Shanghai, including mingcode biology, Dingjing medicine, tianjingsheng, etc.; the number of financing disclosed in Guangdong is second only to Shanghai, with 40 times of clear disclosure, involving financing enterprises Industries such as: Weiguang biology, Ruilai biology, Zhenluo technology, etc In addition, Zhejiang and Jiangsu disclosed 23 and 21 financing respectively From the perspective of industry segmentation financing, in the first half of 2017, there were 105 times of financing in the medical service industry, involving about 5.794 billion yuan There were 37 financing cases in the pharmaceutical industry, and the amount of financing was clearly disclosed to be about 12.045 billion yuan Among them, medical big data, mobile medicine, health management, contract outsourcing organization, and biological medicine / products are the top 5 sub fields in terms of the number of financing Among them, medical big data (including artificial intelligence) enterprises have become the biggest winners in the financing of life and health industry in the first half of 2017, with 33 enterprises completing the financing In the first half of 2017, top 10 enterprises of life and health industry financing amount were mainly concentrated in the field of artificial intelligence and targeted drugs, and the financing stage was mainly focused on round B and later, with the minimum financing amount of 270 million yuan Detailed explanation on financing of life and health industry segmentation pharmaceutical in H1 pharmaceutical field in 2017, 37 financing were disclosed, with a clear disclosure of the financing amount of about 12.045 billion yuan The highest financing was the strategic financing of 5.6 billion yuan of Jiangsu Yuyue medical investment for Yunnan Baiyao Pharmaceutical Group From the point of view of financing stage, domestic pharmaceutical financing is concentrated in the middle and later stage From the perspective of pharmaceutical industry segmentation, pharmaceutical outsourcing organization industry has become a hot area of concern due to industry policies, new drug market and other factors In the first half of 2017, the pharmaceutical R & D outsourcing Organization (CRO) disclosed six times of financing, including one enterprise listed, two enterprises were heavily merged and three enterprises completed financing Biologics occupy an important position in the global drug market At present, the market scale keeps rapid growth, and the corresponding market of biologics R & D service has huge potential It is estimated that the domestic market scale will increase from 2.1 billion yuan in 2016 to 9.2 billion yuan in 2021 Yao Ming biology announced on May 29 that it would officially enter the Hong Kong stock market As a leading domestic bio pharmaceutical cro enterprise, Yaoming bio occupies about 1.8% of the global market share and 48% of the domestic market share In 2017, the H1 medical device field disclosed 24 financing transactions, with a clear disclosure of the financing amount of about 368 million yuan Among them, 10 financing cases were disclosed in the field of medical imaging The combination of medical image and artificial intelligence has become a hot area of concern, and is expected to become the first clinical application in the field of artificial intelligence The financing stage is mainly concentrated in the early stage of the project, in which 5 cases have clearly disclosed the financing amount, and the average amount of a single case is about RMB 33 million Hangzhou Jianpei Technology Co., Ltd is committed to the research, development and application of medical image big data analysis technology (Miba) Now it has formed a "smart health" ecosystem with medical image output, intelligent medical treatment and intelligent diagnosis as the main, and other big data support equipment and platform construction as the auxiliary On July 21, 2017, its film reading robot once again set a new world record with a false-positive rate of 91.6% The latest results have been integrated into the healthview diagnostic cloud for clinical use In vitro diagnosis 2017 H1 domestic in vitro diagnosis field disclosed 10 financing, with a single financing amount of about 846 million yuan, and the highest financing is round B financing of 270 million yuan of sharp bio Among them, 8 kinds of financing were disclosed in the field of gene sequencing, with an average financing amount of about 935 million yuan The proportion of seed round / Angel round financing was reduced The financing stage was mainly focused on round B, and Lianchuan biology and Yuanyi gene successively listed new three boards It can be seen that the industry leaders are accelerating the effect of industrial resource agglomeration, and precision medicine is accelerating its implementation On July 14, 2017, BGI, the leader of gene sequencing in China, officially landed on the gem of Shenzhen Stock Exchange, becoming the first share of the real gene sequencing industry landing in the capital market Its core business involves basic research and clinical application services of reproductive health, basic scientific research services, complex disease research and clinical application products, as well as basic research and clinical application services of drugs Among them, reproductive gene sequencing is the most mature application, with revenue of 929 million in 2016, accounting for 54.62% of total sales In 2017, H1, the property of "medical peripheral services" of domestic medical service enterprises gradually broke through In the field, 105 financing was disclosed, with a single financing amount of about 840 million yuan The highest financing was the 200 million USD round D financing of interactive peak Technology (Beijing) Co., Ltd (Haofu online) Among them, 34 financing cases were disclosed in the field of medical artificial intelligence, and the total amount of financing was about 2.22 billion yuan The application of artificial intelligence in drug research and development, intelligent robot, intelligent diagnosis, health management and so on is changing the medical industry imperceptibly Dachi technology is the first cloud intelligent robot operator in the world It focuses on the security cloud computing network, large hybrid artificial intelligence machine learning platform, and the research of security intelligent terminal and robot controller technology to realize the interaction of patients, medical personnel, medical institutions and medical equipment, and realize the optimal allocation of medical resources Quickly promote the transformation and upgrading of medical industry from traditional industry to modern service industry In 2017, 21 companies in the life and health industry completed IPO / new third board listing in H1 medical capital market, among which 12 companies related to drugs (including health products) had IPO / new third board listing In general, the medical capital market in 2017h1 is in a double hot and cold situation Capital is attributed to rationality, strong liquidity, and sufficient technology accumulation Those projects that solve the core problems of medical treatment are chased by capital The CSRC accelerated the examination of IPO and broadened the exit channels for VC / PE.